After a median follow-up period of 273 days, individuals who underwent FIRM-guided ablation experienced a significantly higher independence from AF after a single procedure than those that underwent standard ablation, at 82.4 percent versus 44.9 percent . ‘The results of the trial, with an 80 percent ablation success price after a single procedure, have become gratifying,’ remarked co-writer Kalyanam Shivkumar . ‘This is the dawn of a fresh phase of controlling this common arrhythmia that’s mechanism-based.’ The FIRM technology was certified to Topera Medical, which includes recently obtained US Food and Drug Administration clearance for the arrhythmia source mapping program. Certified from medwireNews with permission from Springer Health care Ltd. All privileges reserved. Neither of the parties endorse or suggest any commercial products, services, or equipment..In today’s randomized, placebo-controlled, dose-ranging phase 2 study, we evaluated the pharmacodynamic profile of ISIS 304801 as monotherapy and as an add-on to stable dosages of fibrate therapy in individuals with severe or uncontrolled hypertriglyceridemia. Strategies Study Design This phase 2, randomized, double-blind, placebo-controlled, dose-ranging study was made to evaluate the pharmacodynamic ramifications of ISIS 304801 on fasting APOC3 levels in adult patients with severe or uncontrolled hypertriglyceridemia. Sufferers who were not receiving triglyceride-lowering therapy had been considered eligible if indeed they experienced fasting triglyceride levels between 350 mg per deciliter and 2000 mg per deciliter; patients who were finding a stable dose of fibrate were eligible if they acquired fasting triglyceride levels between 225 mg per deciliter and 2000 mg per deciliter.